AstraZeneca India opened a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials. The clinical data & insights team in Bengaluru, India, is a critical advancement to support a growing global portfolio, and build on internal data expertise.

Reporting into Development Operations in Biopharmaceuticals R&D, the team will be responsible for the management of data-related aspects of AstraZeneca's clinical trials, excluding analysis and reporting. CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights and risk management. Currently a 30-member team, the division is expected to grow to over 100 member strong team by 2022.

Commenting on the launch of the CDI division in India, Siva Padmanabhan, Managing Director, AstraZeneca India, said, “The role of the Global Capability Centre (GCC) in the overall growth of the parent organisation is witnessing a shift. Over the last decade, GCCs in India are undertaking more strategic and transformative work critical to the success of the organisation. Since its inception, AstraZeneca India has supported the global organisation with various services spanning IT, Business Services and R&D from our centres in Chennai and Bengaluru, on transformative projects.’’

Commenting on setting up a CDI division in India, Natalie Fishburn, Vice President, Global Head of Clinical Data & Insights, AstraZeneca, said, "Clinical data and insight solutions enable pharmaceutical organisations such as ours to gain in-depth visibility into the patient's journey by extracting actionable insights from disparate data sources. The establishment of the CDI division in India is key to our strategic vision of being industry leaders in this space.